PHS
CRL icon

Pekin Hardy Strauss’s Charles River Laboratories CRL Stock Holding History

Pekin Hardy Strauss’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Sell
6,157
-2,807
-31% -$520K 0.11% 201
2025
Q4 		$1.79M Sell
8,964
-27,096
-75% -$4.92M 0.17% 135
2025
Q3 		$5.64M Sell
36,060
-2,331
-6% -$370K 0.57% 46
2025
Q2 		$5.83M Buy
38,391
+14,996
+64% +$2M 0.66% 43
2025
Q1 		$3.52M Buy
+23,395
New +$3.92M 0.43% 64

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Pekin Hardy Strauss's CRL Position: Q1 2026 in Review

Pekin Hardy Strauss reduced its Charles River Laboratories (CRL) stake by 31% in Q1 2026, selling an estimated $520K and leaving 6,157 shares worth $1.06M. The position accounts for 0.11% of the portfolio, ranked #201.

Pekin Hardy Strauss first reported a position in CRL in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.83M in Q2 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Pekin Hardy Strauss held 6,157 shares of Charles River Laboratories worth $1.06M as of Q1 2026.
  • Pekin Hardy Strauss sold 2,807 Charles River Laboratories shares in Q1 2026, an estimated $520K.
  • Charles River Laboratories made up 0.11% of Pekin Hardy Strauss's portfolio in Q1 2026, its #201 holding.
  • Pekin Hardy Strauss first reported a position in Charles River Laboratories in Q1 2025 and has held it in 5 quarters since.
  • Pekin Hardy Strauss's Charles River Laboratories position peaked at $5.83M in Q2 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Pekin Hardy Strauss's 13F filing for Q1 2026, filed 7 May 2026.